Targeting BRAF in thyroid cancer

Mostrar otras versiones (1)

Activating mutations in the gene encoding BRAF are the most commonly identified oncogenic abnormalities in papillary thyroid cancer. In vitro and in vivo models have demonstrated that overexpression of activated BRAF induces malignant transformation and aggressive tumour behaviour. BRAF and other RA...

Descripción completa

Detalles Bibliográficos
Autores principales: Espinosa, A V, Porchia, L, Ringel, M D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360215/
https://www.ncbi.nlm.nih.gov/pubmed/17179987
http://dx.doi.org/10.1038/sj.bjc.6603520
_version_ 1782152993108393984
author Espinosa, A V
Porchia, L
Ringel, M D
author_facet Espinosa, A V
Porchia, L
Ringel, M D
author_sort Espinosa, A V
collection PubMed
description Activating mutations in the gene encoding BRAF are the most commonly identified oncogenic abnormalities in papillary thyroid cancer. In vitro and in vivo models have demonstrated that overexpression of activated BRAF induces malignant transformation and aggressive tumour behaviour. BRAF and other RAF kinases are frequently activated by other thyroid oncogenes and are important mediators of their biological effects including dedifferentiation and proliferation. Because current therapeutic options for patients with thyroid cancers that are aggressive and/or do not respond to standard therapies are limited, BRAF and its downstream effectors represent attractive therapeutic targets. In this review, data supporting a role for BRAF activation in thyroid cancer development and establishing the potential therapeutic efficacy of BRAF-targeted agents in patients with thyroid cancer will be reviewed.
format Text
id pubmed-2360215
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23602152009-09-10 Targeting BRAF in thyroid cancer Espinosa, A V Porchia, L Ringel, M D Br J Cancer Minireview Activating mutations in the gene encoding BRAF are the most commonly identified oncogenic abnormalities in papillary thyroid cancer. In vitro and in vivo models have demonstrated that overexpression of activated BRAF induces malignant transformation and aggressive tumour behaviour. BRAF and other RAF kinases are frequently activated by other thyroid oncogenes and are important mediators of their biological effects including dedifferentiation and proliferation. Because current therapeutic options for patients with thyroid cancers that are aggressive and/or do not respond to standard therapies are limited, BRAF and its downstream effectors represent attractive therapeutic targets. In this review, data supporting a role for BRAF activation in thyroid cancer development and establishing the potential therapeutic efficacy of BRAF-targeted agents in patients with thyroid cancer will be reviewed. Nature Publishing Group 2007-01-15 2006-12-19 /pmc/articles/PMC2360215/ /pubmed/17179987 http://dx.doi.org/10.1038/sj.bjc.6603520 Text en Copyright © 2007 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Minireview
Espinosa, A V
Porchia, L
Ringel, M D
Targeting BRAF in thyroid cancer
title Targeting BRAF in thyroid cancer
title_full Targeting BRAF in thyroid cancer
title_fullStr Targeting BRAF in thyroid cancer
title_full_unstemmed Targeting BRAF in thyroid cancer
title_short Targeting BRAF in thyroid cancer
title_sort targeting braf in thyroid cancer
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360215/
https://www.ncbi.nlm.nih.gov/pubmed/17179987
http://dx.doi.org/10.1038/sj.bjc.6603520
work_keys_str_mv AT espinosaav targetingbrafinthyroidcancer
AT porchial targetingbrafinthyroidcancer
AT ringelmd targetingbrafinthyroidcancer

Ejemplares similares